LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引：1
|
作者：
Mcinnes, I. [1 ]
Kato, K. [2 ]
Magrey, M. [3 ]
Merola, J. F. [4 ,5 ]
Kishimoto, M. [6 ]
Haaland, D. [7 ,8 ]
Chen, L. [2 ]
Duan, Y. [2 ]
Liu, J. [2 ]
Lippe, R. [9 ]
Wung, P. [2 ]
机构：
[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[2] AbbVie Inc, Immunol, N Chicago, IL USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Harvard Med Sch, Dermatol & Rheumatol, Boston, MA 02115 USA
[6] Kyoto Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[7] McMaster Univ, Hamilton, ON, Canada
[8] Waterside Clin, Rheumatol & Clin Immunol Allergy, Barrie, ON, Canada
[9] AbbVie Deutschland GmbH Co KG, Immunol, Wiesbaden, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.799
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0081
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [31] Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
    Fleischmann, Roy
    Swierkot, Jerzy
    Penn, Sara K.
    Durez, Patrick
    Bessette, Louis
    Bu, Xianwei
    Khan, Nasser
    Li, Yihan
    Peterfy, Charles G.
    Tanaka, Yoshiya
    Mysler, Eduardo
    RMD OPEN, 2024, 10 (02):
  • [32] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY
    Fleischmann, R. M.
    Swierkot, J.
    Penn, S.
    Durez, P.
    Bessette, L.
    Bu, X.
    Khan, N.
    Li, Y.
    Peterfy, C.
    Tanaka, Y.
    Mysler, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 725 - 726
  • [33] Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
    Coates, Laura
    Bakewell, Catherine
    Khraishi, Majed
    Chen, Shirley
    Gao, Tianming
    Setty, Arathi
    Jones, Heather
    Ciecinski, Sandra
    Mysler, Eduardo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2793 - 2795
  • [34] COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1
    Smolen, J. S.
    Lubrano, E.
    Kishimoto, M.
    Balanescu, A.
    Strand, V.
    Gao, T.
    Vranich, N.
    Lippe, R.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 824 - 824
  • [35] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Thaci, Diamant
    Gottlieb, Alice B.
    Asahina, Akihiko
    Lebwohl, Mark
    McInnes, Iain B.
    Warren, Richard
    Boehncke, Wolf-Henning
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph F.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [36] Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis (PsA): 2-year results from an openlabel extension study
    Mease, Philip
    Ritchlin, Christopher
    Wong, Robert
    Gladman, Dafna
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB4 - AB4
  • [37] Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
    Smolen, Josef
    Lubrano, Ennio
    Kishimoto, Mitsumasa
    Balanescu, Andra R.
    Strand, Vibeke
    Gao, Tianming
    Vranich, Nancy
    Lippe, Ralph
    Tillett, William
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3790 - 3792
  • [38] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-NEXT STUDY
    Burmester, Gerd Ruediger
    van den Bosch, Filip
    Bessette, Louis
    Kivitz, Alan
    Li Yihan
    Friedman, Alan
    Pangan, Aileen
    Camp, Heidi
    Kremer, Joel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 735 - 736
  • [39] LONG-TERM SAFETY AND EFFICACY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): 2-YEAR RESULTS FROM A LONG-TERM STUDY
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian
    Levy, Cynthia
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Steinberg, Alexandra
    Xu, Emily
    Yang, Ke
    Choi, Yun-Jung
    Dickinson, Klara
    McWherter, Charles
    HEPATOLOGY, 2021, 74 : 71A - 73A
  • [40] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Baraliakos, Xenofon
    Ranza, Roberto
    Ostor, Andrew
    Ciccia, Francesco
    Coates, Laura C.
    Rednic, Simona
    Walsh, Jessica A.
    Douglas, Kevin
    Gao, Tianming
    Kato, Koji
    Song, In-Ho
    Ganz, Fabiana
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
12345